Rebecca L Tisdale1,2, Marika M Cusick3, Kelly Zhang Aluri4,5, Thomas J Handley3,6,7, Alice Kate Cummings Joyner8, Joshua A Salomon3, Glenn M Chertow3,4,9, Jeremy D Goldhaber-Fiebert3, Douglas K Owens3. 1. VA Palo Alto Health Care System (152-MPD), Health Services Research and Development (HSR&D), Center for Innovation to Implementation (Ci2i), 795 Willow Road, Building 324, Menlo Park, CA, 94025, USA. rtisdale@stanford.edu. 2. Department of Health Policy, School of Medicine, and Center for Health Policy, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CA, USA. rtisdale@stanford.edu. 3. Department of Health Policy, School of Medicine, and Center for Health Policy, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CA, USA. 4. Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA. 5. Stanford University School of Medicine, Stanford, CA, USA. 6. Department of Surgery and Cancer, Imperial College London, London, UK. 7. Stanford-Surgery Policy Improvement Research & Education (S-SPIRE) Center, Stanford, CA, USA. 8. Department of Management Science and Engineering, Stanford University, Stanford, CA, USA. 9. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Abstract
BACKGROUND: In the USA, chronic kidney disease (CKD) affects 1 in 7 adults and costs $100 billion annually. The DAPA-CKD trial found dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, to be effective in reducing CKD progression and mortality in patients with diabetic and non-diabetic CKD. Currently, SGLT2 inhibitors are not considered standard of care for patients with non-diabetic CKD. OBJECTIVE: Determine the cost-effectiveness of adding dapagliflozin to standard management of patients with non-diabetic CKD. DESIGN: Markov model with lifetime time horizon and US healthcare sector perspective. PATIENTS: Patients with non-diabetic CKD INTERVENTION: Dapagliflozin plus standard care versus standard care only. MAIN MEASURES: Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs), all discounted at 3% annually; total incidence of kidney failure on kidney replacement therapy; average years on kidney replacement therapy. KEY RESULTS: Adding dapagliflozin to standard care improved life expectancy by 2 years, increased discounted QALYS (from 6.75 to 8.06), and reduced the total incidence of kidney failure on kidney replacement therapy (KRT) (from 17.4 to 11.0%) and average years on KRT (from 0.77 to 0.43) over the lifetime of the cohort. Dapagliflozin plus standard care was more effective than standard care alone while increasing lifetime costs (from $245,900 to $324,8900, or $60,000 per QALY gained). Results were robust to variations in assumptions about dapagliflozin's efficacy over time and by CKD stage, added costs of kidney replacement therapy, and expected population annual CKD progression rates and sensitive to the cost of dapagliflozin. The net 1-year budgetary implication of treating all US patients with non-diabetic CKD could be up to $21 billion. CONCLUSIONS: Dapagliflozin improved life expectancy and reduced progression of CKD, the proportion of patients requiring kidney replacement therapy, and time on kidney replacement therapy in patients with non-diabetic CKD. Use of dapagliflozin meets conventional criteria for cost-effectiveness.
BACKGROUND: In the USA, chronic kidney disease (CKD) affects 1 in 7 adults and costs $100 billion annually. The DAPA-CKD trial found dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, to be effective in reducing CKD progression and mortality in patients with diabetic and non-diabetic CKD. Currently, SGLT2 inhibitors are not considered standard of care for patients with non-diabetic CKD. OBJECTIVE: Determine the cost-effectiveness of adding dapagliflozin to standard management of patients with non-diabetic CKD. DESIGN: Markov model with lifetime time horizon and US healthcare sector perspective. PATIENTS: Patients with non-diabetic CKD INTERVENTION: Dapagliflozin plus standard care versus standard care only. MAIN MEASURES: Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs), all discounted at 3% annually; total incidence of kidney failure on kidney replacement therapy; average years on kidney replacement therapy. KEY RESULTS: Adding dapagliflozin to standard care improved life expectancy by 2 years, increased discounted QALYS (from 6.75 to 8.06), and reduced the total incidence of kidney failure on kidney replacement therapy (KRT) (from 17.4 to 11.0%) and average years on KRT (from 0.77 to 0.43) over the lifetime of the cohort. Dapagliflozin plus standard care was more effective than standard care alone while increasing lifetime costs (from $245,900 to $324,8900, or $60,000 per QALY gained). Results were robust to variations in assumptions about dapagliflozin's efficacy over time and by CKD stage, added costs of kidney replacement therapy, and expected population annual CKD progression rates and sensitive to the cost of dapagliflozin. The net 1-year budgetary implication of treating all US patients with non-diabetic CKD could be up to $21 billion. CONCLUSIONS: Dapagliflozin improved life expectancy and reduced progression of CKD, the proportion of patients requiring kidney replacement therapy, and time on kidney replacement therapy in patients with non-diabetic CKD. Use of dapagliflozin meets conventional criteria for cost-effectiveness.
Authors: P Ruggenenti; A Perna; G Gherardi; G Garini; C Zoccali; M Salvadori; F Scolari; F P Schena; G Remuzzi Journal: Lancet Date: 1999-07-31 Impact factor: 79.321
Authors: Robert M Perkins; Ion D Bucaloiu; H Lester Kirchner; Nasrin Ashouian; James E Hartle; Taher Yahya Journal: Clin J Am Soc Nephrol Date: 2011-06-16 Impact factor: 8.237
Authors: Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Peter Stein; Mehul Desai; Wayne Shaw; Joel Jiang; Frank Vercruysse; Gary Meininger; David Matthews Journal: Am Heart J Date: 2013-06-24 Impact factor: 4.749
Authors: Hiddo J L Heerspink; C David Sjöström; Niels Jongs; Glenn M Chertow; Mikhail Kosiborod; Fan Fan Hou; John J V McMurray; Peter Rossing; Ricardo Correa-Rotter; Raisa Kurlyandskaya; Bergur V Stefansson; Robert D Toto; Anna Maria Langkilde; David C Wheeler Journal: Eur Heart J Date: 2021-03-31 Impact factor: 29.983
Authors: William G Herrington; David Preiss; Richard Haynes; Maximilian von Eynatten; Natalie Staplin; Sibylle J Hauske; Jyothis T George; Jennifer B Green; Martin J Landray; Colin Baigent; Christoph Wanner Journal: Clin Kidney J Date: 2018-10-25
Authors: Shan Liu; Paul G Barnett; Mark Holodniy; Jeanie Lo; Vilija R Joyce; Risha Gidwani; Steven M Asch; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: MDM Policy Pract Date: 2016-10-03